Effect of Low Glycemic Index Diet on Biochemical Parameters and Body Image in Obesity With Insulin Resistance: A Randomized Clinical Trial

Low Glycemic Index Diet Effects in Obesity With Insulin Resistance

To examine how a low glycemic index diet (LGID) changes biochemical parameters, body measurements, and body image perception in obese individuals with insulin resistance. Obesity groups with insulin resistance who received a control diet (CD) and a LGID will be compared with each other in terms of biochemical parameters, body image perception and body measurements. In addition, each group will be compared with the start and end measurements over the same values.

Study Overview

• Status: Completed
• Conditions: Obesity
• Intervention / Treatment: Behavioral: Low Glycemic Index Diet

Detailed Description

The main purpose of this study is to determine the effect of LGID on body image perception, biochemical parameters and body measurements in obese individuals with insulin resistance.

Sub-objectives of the study;

Determination of the effect of LGID on fasting blood glucose, fasting insulin level and HOMA-IR levels compared to CD.

Determination of the effect of LGID on body weight, fat mass, muscle mass, body muscle ratio and body mass index (BMI) compared to CD.

Determination of the effect of LGID on body image perception status compared to CD.

• Study Type: Interventional
• Enrollment (Actual): 124
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey
  • İstanbul, Turkey, 34672
    • Uskudar University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• BMI above 24 kg/m2, or the either one (fat mass ≧ 30% or waistline > 80 cm)
• Can provide informed consent
• Can be contacted by telephone
• Waist circumference > 90 cm for men and > 80 cm for women

Exclusion Criteria:

• Pregnancy or lactation
• Active or suspected chronic infection
• Treatment affecting insulin sensitivity
• A secondary disease state (Cardiovascular disease, cancer, psychiatric, etc.)
• Any weight loss operation (gastric bypass, gastric balloon, etc.)
• A special nutritional program (cancer, kidney disease, etc.)
• Using any food supplement or medication known to affect whole body metabolism

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Control Diet; For the Control Diet, a medical nutrition therapy with calorie and fat content was prepared to ensure weight loss of individuals without considering the glycemic index.; The aim of this diet is to achieve weight loss, but not to focus on the content of carbohydrates. 3) In the macro element distribution of the CD, 50-55% carbohydrates, 10-15% protein and 20-25% fat distribution Other name (CD Group)

Behavioral: Low Glycemic Index Diet; Participants who came to the hospital for control and were interested in the study contacted the study researchers and eligibility was determined through face-to-face interviews. Potential participants were invited to a screening visit to verify eligibility.; The LGID program was initiated as an outpatient treatment in patients who applied to a dietitian. 3) Medium and high GI carbohydrates (GI > 55) were excluded from the diet and only low GI (GI < 50) foodstuffs were allowed. 4) A list of low glycemic index foods were given to the patients. In addition, a list of foods to avoid (medium and high glycemic index) is provided.; Other Names: LGID Group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Homeostatic Model Assessment for Insulin Resistance	Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) index was obtained by the following formula: fasting glucose (mg/dl/18) x fasting insulin (U/mL)/22.5. A HOMA-IR index >2.5 is in favor of Insulin Resistance (IR).	Changes within and between groups are evaluated on the start and last day of the intervention (day 120).
Cholesterol	Blood samples were collected after an overnight fast by using 10 mL plain tubes. Lipid profile was measured by using Cholesterol Kits and total cholesterol levels were measured using the sum of the LDL and HDL plus one-fifth of triglyceride levels.	Changes within and between groups are evaluated on the start and last day of the intervention (day 120).
Fasting plasma glucose	Fasting plasma glucose (FPG) levels were determined by taking a blood sample from participants who have fasted for at least 8 hours, Fasting glucose is between 75-95 mg/dL (4.2-5.3 mmol/L).	Changes within and between groups are evaluated on the start and last day of the intervention (day 120).
Fasting insulin level	Fasting insulin is between 18-48 pmol/L.	Changes within and between groups are evaluated on the start and last day of the intervention (day 120).
Body weight	Body weight was measured in kilograms.	Changes within and between groups are evaluated on the start and last day of the intervention (day 120).
Body muscle ratio	Body muscle ratio as assessed by bioelectrical impedance analysis -- whole body composition was evaluated.	Changes within and between groups are evaluated on the start and last day of the intervention (day 120).
Body muscle mass, kg	Body muscle mass as assessed by bioelectrical impedance analysis -- whole body composition was evaluated.	Changes within and between groups are evaluated on the start and last day of the intervention (day 120).
Body mass index	Body mass index (BMI)=weight/(height)^2	Changes within and between groups are evaluated on the start and last day of the intervention (day 120).
Body fat mass, kg	Body fat mass as assessed by bioelectrical impedance analysis -- whole body composition was evaluated.	Changes within and between groups are evaluated on the start and last day of the intervention (day 120).
Body fat ratio	Body fat ratio as assessed by bioelectrical impedance analysis -- whole body composition was evaluated.	Changes within and between groups are evaluated on the start and last day of the intervention (day 120).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of body image scale	The body image scale (BIS) includes 10 items, and was developed to briefly and comprehensively assess the affective (e.g., feeling self-conscious), behavioral (e.g., difficulty in looking at the naked body), and cognitive (e.g., satisfaction with appearance) aspects of body image in patients. It is a 4-point scale (0 = not at all and 3 = very much), and the final score is the sum of scores for 10 items, ranging from 0 to 30, with a lower score representing a better body image.	Changes within and between groups are evaluated on the start and last day of the intervention (day 120).

Collaborators and Investigators

• Sponsor: Uskudar University

Study record dates

Study Major Dates

• Study Start (Actual): February 20, 2022
• Primary Completion (Actual): May 24, 2022
• Study Completion (Actual): August 2, 2023

Study Registration Dates

• First Submitted: March 12, 2023
• First Submitted That Met QC Criteria: March 25, 2023
• First Posted (Actual): March 28, 2023

Study Record Updates

• Last Update Posted (Estimated): November 3, 2023
• Last Update Submitted That Met QC Criteria: October 31, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Keywords: Obesity; Low Glycemic Load Diet
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Overnutrition; Nutrition Disorders; Overweight; Body Weight; Hyperinsulinism; Obesity; Insulin Resistance
• Other Study ID Numbers: UskudarUBesYA02

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No